Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer. Panelists examine the ...

It's dangerous in medicine to make decisions based solely on what makes intuitive sense. At the European Society of Cardiology (ESC) Congress 2023, we learned from the BUDAPEST CRT trial that the ...

Patients with advanced/refractory cancers treated with genomically matched therapies had better overall survival only when the treatments had support from prospective studies, a large multicenter ...